Catabasis Pharmaceuticals Inc. (CATB)

7.30
NASDAQ : Health Technology
Prev Close 7.46
Day Low/High 7.17 / 7.63
52 Wk Low/High 3.60 / 20.69
Avg Volume 296.60K
Exchange NASDAQ
Shares Outstanding 11.50M
Market Cap 85.76M
EPS -5.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Catabasis Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results And Recent Corporate Developments On Thursday, March 14

Catabasis Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results And Recent Corporate Developments On Thursday, March 14

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2018 financial results before the Nasdaq Global Market open on Thursday, March 14, 2019.

Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent As A Potential Foundational Treatment For Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent As A Potential Foundational Treatment For Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared additional clinical results from the MoveDMD trial of edasalonexent.

Catabasis Pharmaceuticals Appoints Joanne T. Beck To Its Board Of Directors

Catabasis Pharmaceuticals Appoints Joanne T. Beck To Its Board Of Directors

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T.

Catabasis Pharmaceuticals Announces Pricing Of $20 Million Underwritten Public Offering

Catabasis Pharmaceuticals Announces Pricing Of $20 Million Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. ("Catabasis," the "Company," "we," "our," or "us") (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a public...

Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. ("Catabasis," the "Company," "we," "our," or "us") (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering.

Catabasis Pharmaceuticals Appoints Gregg Lapointe To Its Board Of Directors

Catabasis Pharmaceuticals Appoints Gregg Lapointe To Its Board Of Directors

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Gregg Lapointe to its Board of Directors.

Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy Progress Update And Additional Trial Sites Open For Enrollment

Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy Progress Update And Additional Trial Sites Open For Enrollment

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD...

Catabasis Pharmaceuticals Announces Reverse Stock Split

Catabasis Pharmaceuticals Announces Reverse Stock Split

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will effect a one-for-ten reverse stock split of its common stock that will be effective on December 28, 2018.

Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published in the Journal of Neuromuscular Diseases, "Phase 1 Study of...

Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results And Reviews Business Progress

Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results And Reviews Business Progress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2018, and reviewed recent business progress.

Catabasis Pharmaceuticals Announces Collaboration With The University Of Texas Southwestern To Explore The Potential Benefits Of Edasalonexent On Cardiac Function In Duchenne And Becker Muscular Dystrophies

Catabasis Pharmaceuticals Announces Collaboration With The University Of Texas Southwestern To Explore The Potential Benefits Of Edasalonexent On Cardiac Function In Duchenne And Becker Muscular Dystrophies

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced a collaboration with Pradeep Mammen, MD, FACC, FAHA, founder and Medical Director of the Neuromuscular Cardiomyopathy Clinic at the University of...

Catabasis Pharmaceuticals And Parent Project Muscular Dystrophy To Host A Webinar On PolarisDMD: Phase 3 Clinical Trial Of Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals And Parent Project Muscular Dystrophy To Host A Webinar On PolarisDMD: Phase 3 Clinical Trial Of Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar: "PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor, in Duchenne...

Catabasis Pharmaceuticals To Report Third Quarter 2018 Financial Results And Recent Corporate Developments On Tuesday, November 13

Catabasis Pharmaceuticals To Report Third Quarter 2018 Financial Results And Recent Corporate Developments On Tuesday, November 13

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2018 financial results before the Nasdaq Global Market open on Tuesday, November 13, 2018.

Catabasis Pharmaceuticals Presents Data Supporting MRI T2 As A Potential Marker Of Clinical Outcome In Duchenne Muscular Dystrophy At The World Muscle Society Congress

Catabasis Pharmaceuticals Presents Data Supporting MRI T2 As A Potential Marker Of Clinical Outcome In Duchenne Muscular Dystrophy At The World Muscle Society Congress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new data supporting magnetic resonance imaging (MRI) T2 as a potential marker of clinical outcome in boys with Duchenne Muscular Dystrophy (DMD).

Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of PolarisDMD, the Company's Phase 3 trial for edasalonexent in Duchenne muscular dystrophy (DMD).

Catabasis Pharmaceuticals To Present New Edasalonexent Clinical Results And Phase 3 Trial Design In Duchenne Muscular Dystrophy At The World Muscle Society Congress

Catabasis Pharmaceuticals To Present New Edasalonexent Clinical Results And Phase 3 Trial Design In Duchenne Muscular Dystrophy At The World Muscle Society Congress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will share three presentations, including in the late breaking session, at the 23 rd International Congress of the World Muscle...

Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results And Reviews Business Progress

Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results And Reviews Business Progress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2018, and reviewed recent business progress.

Catabasis Pharmaceuticals To Present At 2018 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals To Present At 2018 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C.

Catabasis Pharmaceuticals To Report Second Quarter 2018 Financial Results And Recent Corporate Developments On Thursday, August 9

Catabasis Pharmaceuticals To Report Second Quarter 2018 Financial Results And Recent Corporate Developments On Thursday, August 9

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2018 financial results before the NASDAQ Global Market open on Thursday, August 9, 2018.

Catabasis Pharmaceuticals Announces Plans For Edasalonexent Phase 3 POLARIS DMD Trial In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals Announces Plans For Edasalonexent Phase 3 POLARIS DMD Trial In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced plans for the Phase 3 POLARIS DMD trial with edasalonexent in patients with Duchenne muscular dystrophy (DMD).

Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition And Target Engagement In The MoveDMD® Trial

Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition And Target Engagement In The MoveDMD® Trial

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected...

Catabasis Pharmaceuticals Announces Closing Of $42M Underwritten Public Offering

Catabasis Pharmaceuticals Announces Closing Of $42M Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of an aggregate of 42,000,000 units.

Catabasis Pharmaceuticals Announces Pricing Of $42 Million Underwritten Public Offering

Catabasis Pharmaceuticals Announces Pricing Of $42 Million Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. ("Catabasis," the "Company," "we," "our," or "us") (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten offering of an aggregate of 42,000,000 units.

Catabasis Pharmaceuticals To Present At Upcoming Scientific And Advocacy Conferences

Catabasis Pharmaceuticals To Present At Upcoming Scientific And Advocacy Conferences

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from the MoveDMD ® trial of edasalonexent (CAT-1004) at the New Directions in Biology and Disease of Skeletal Muscle...

Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results And Reviews Business Progress

Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results And Reviews Business Progress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2018, and reviewed recent business progress.

Catabasis Pharmaceuticals To Report First Quarter 2018 Financial Results And Recent Corporate Developments On Thursday, May 10

Catabasis Pharmaceuticals To Report First Quarter 2018 Financial Results And Recent Corporate Developments On Thursday, May 10

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2018 financial results before the NASDAQ Global Market open on Thursday, May 10, 2018.

(Graphic: Business Wire)

(Graphic: Business Wire)

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne muscular dystrophy (DMD) in the MoveDMD...

Catabasis Pharmaceuticals To Present At Oppenheimer's 28th Annual Healthcare Conference

Catabasis Pharmaceuticals To Present At Oppenheimer's 28th Annual Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C.